...
首页> 外文期刊>Neuroendocrinology: International Journal for Basic and Clinical Studies on Neuroendocrine Relationships >Prolactin-Releasing Peptide Releases Corticotropin-Releasing Hormone and Increases Plasma Adrenocorticotropin via the Paraventricular Nucleus of the Hypothalamus.
【24h】

Prolactin-Releasing Peptide Releases Corticotropin-Releasing Hormone and Increases Plasma Adrenocorticotropin via the Paraventricular Nucleus of the Hypothalamus.

机译:催乳激素释放肽通过下丘脑室旁核释放促肾上腺皮质激素释放激素并增加血浆肾上腺皮质激素。

获取原文
获取原文并翻译 | 示例

摘要

Intracerebroventricular (ICV) injection of prolactin-releasing peptide (PrRP) is known to increase plasma adrenocorticotropin (ACTH) and cause c-fos expression in the hypothalamic paraventricular nucleus (PVN). We hypothesize that this is the site at which PrRP acts to increase plasma ACTH. We have used ICV injection and direct intranuclear injection of PrRP into the PVN to investigate the sites important in the stimulation of ACTH release in vivo. To investigate the mechanism of action by which PrRP increases ACTH, we have used primary culture of pituitary cells and measured neuropeptide release from in vitro hypothalamic incubations. ICV administration of PrRP increased plasma ACTH 10 min post-injection (PrRP 5 nmol 81.0 +/- 23.5 pg/ml vs. saline 16.8 +/- 14.1 pg/ml, p < 0.05). Intra-PVN injection of PrRP increased ACTH 5 min post-injection (PrRP 1 nmol 22.9 +/- 5.0 pg/ml vs. saline 10.3 +/- 1.4 pg/ml, p < 0.05). This effect continued until 40 min post-injection (PrRP 1 nmol 9.9 +/- 1.5 pg/ml vs. saline 6.2 +/- 0.5 pg/ml, p < 0.05). In vitro PrRP (1-100 nmol/l) did not effect basal or corticotropin-releasing hormone (CRH)-stimulated ACTH release from dispersed anterior pituitary cells. PrRP increased hypothalamic release of CRH (PrRP 100 nmol/l 1.4 +/- 0.2 nmol/explant vs. the basal 1.1 +/- 0.2 nmol/explant, p < 0.05) but not arginine vasopressin. PrRP also stimulated neuropeptide Y release (PrRP 100 nmol/l 56.5 +/- 11.8 pmol/explant vs. basal 24.0 +/- 1.9 pmol/explant, p < 0.01), a neuropeptide known to stimulate the hypothalamo-pituitary-adrenal axis. Our data suggest that in vitro PrRP does not have a direct action on the corticotrope but increases plasma ACTH via the PVN and this effect involves the release of hypothalamic neuropeptides including CRH and neuropeptide Y.
机译:脑室内(ICV)注射催乳激素释放肽(PrRP)会增加血浆肾上腺皮质激素(ACTH)并导致下丘脑室旁核(PVN)中c-fos表达。我们假设这是PrRP起作用以增加血浆ACTH的位点。我们已经使用ICV注射和将PrRP直接核内注射到PVN中来研究在体内刺激ACTH释放中重要的位点。为了研究PrRP增加ACTH的作用机理,我们使用了垂体细胞的原代培养,并测量了体外下丘脑培养物中神经肽的释放。注射后10分钟,ICR给予PrRP会增加血浆ACTH(PrRP 5 nmol为81.0 +/- 23.5 pg / ml,而盐水为16.8 +/- 14.1 pg / ml,p <0.05)。 PVN内注射PrRP会在注射后5分钟增加ACTH(PrRP 1 nmol 22.9 +/- 5.0 pg / ml与盐水10.3 +/- 1.4 pg / ml,p <0.05)。这种作用持续到注射后40分钟为止(PrRP 1 nmol 9.9 +/- 1.5 pg / ml,盐水6.2 +/- 0.5 pg / ml,p <0.05)。体外PrRP(1-100 nmol / l)不会影响基础或促肾上腺皮质激素释放激素(CRH)刺激的ACTH从分散的垂体前叶细胞释放。 PrRP增加了CRH的下丘脑释放(PrRP 100 nmol / l 1.4 +/- 0.2 nmol /植物对基础的1.1 +/- 0.2 nmol /植物,p <0.05),而不是精氨酸加压素。 PrRP还刺激了神经肽Y的释放(PrRP 100 nmol / l 56.5 +/- 11.8 pmol /外植体与基础24.0 +/- 1.9 pmol /外植体,p <0.01),这是一种已知的刺激下丘脑-垂体-肾上腺轴的神经肽。我们的数据表明,体外PrRP对皮质激素没有直接作用,但会通过PVN增加血浆ACTH,这种作用涉及下丘脑神经肽(包括CRH和神经肽Y)的释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号